Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Position Boosted by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC raised its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 133.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 39,331 shares of the biopharmaceutical company's stock after acquiring an additional 22,455 shares during the period. Commonwealth Equity Services LLC's holdings in Catalyst Pharmaceuticals were worth $821,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Rhumbline Advisers boosted its position in shares of Catalyst Pharmaceuticals by 0.3% in the fourth quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company's stock worth $6,518,000 after acquiring an additional 952 shares during the last quarter. Handelsbanken Fonder AB raised its stake in Catalyst Pharmaceuticals by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company's stock worth $740,000 after purchasing an additional 1,000 shares during the period. Steward Partners Investment Advisory LLC acquired a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at $27,000. Farther Finance Advisors LLC grew its stake in shares of Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 1,495 shares during the period. Finally, KBC Group NV increased its holdings in shares of Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after buying an additional 1,542 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Bank of America reiterated a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Stephens reaffirmed an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Finally, HC Wainwright reissued a "buy" rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $32.29.

Catalyst Pharmaceuticals Stock Down 5.5 %

Shares of CPRX traded down $1.26 during mid-day trading on Monday, reaching $21.81. 2,413,254 shares of the stock traded hands, compared to its average volume of 1,128,517. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of 18.48, a P/E/G ratio of 3.31 and a beta of 0.79. The stock has a fifty day simple moving average of $22.76 and a 200 day simple moving average of $21.96. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.47 and a 12-month high of $26.16.

Insider Buying and Selling

In related news, insider Gary Ingenito sold 44,904 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.